Sarcopenia after 40: why preserving muscle mass may mean living longer

Starting around age 40, the body begins to progressively lose muscle mass — somewhere between 3% and 8% per decade, with the pace accelerating further after age 60-65. This process has a name: sarcopenia. And contrary to what many people think, it isn't just a cosmetic issue — it's one of the most studied factors in the relationship between aging and health.

What sarcopenia actually is

Under the most current European consensus on the topic, sarcopenia is defined primarily by loss of muscle strength, confirmed by low muscle quantity or quality, and classified as severe when physical performance (such as walking speed) is also impaired.9 In other words: it's not just about "getting thinner" — it's about losing the muscle's functional capacity.

The link with longevity and mortality

This is the central point: several independent studies, across different countries and populations, have found an association between sarcopenia (or low muscle mass) and risk of death.

• A meta-analysis pooling multiple studies found that people with sarcopenia have roughly twice the risk of mortality compared with those without the condition.10
• A study using NHANES III data (USA) showed that muscle mass index is an independent predictor of longevity in older adults — the higher the relative muscle mass, the lower the all-cause mortality on follow-up.11
• The PURE study, published in The Lancet with nearly 140,000 participants across multiple countries, showed that grip strength (a simple indicator of muscle strength) predicts all-cause and cardiovascular mortality — and, notably, was a stronger predictor than systolic blood pressure.12

Together, these findings point in the same direction: maintaining a good proportion of muscle mass and strength throughout life appears to be associated with living longer and with lower risk of complications from the diseases most common at this stage of life — even though the exact mechanism behind this relationship is still being studied (muscle mass likely reflects, in part, metabolic reserve, functional capacity, and resilience to acute illness).

The connection with weight-loss injections — including in young patients

This topic connects directly to people losing weight with the support of medications like semaglutide or tirzepatide — and that connection isn't limited to older patients.

In the body composition analysis of the STEP 1 trial (semaglutide 2.4 mg, 68 weeks, adults with overweight or obesity), average weight loss was 15.0%, but a meaningful part of it came from lean mass, not just fat.14 In the body composition substudy of SURMOUNT-1 (tirzepatide, 72 weeks), about 25% of all weight lost was lean mass — a 10.9% reduction in lean mass, versus a 33.9% reduction in fat mass.13 A systematic review pooling multiple studies on GLP-1 receptor agonists confirms this pattern consistently across different populations.3

The key point for younger patients: the trials underlying these medications enrolled adults from age 18 onward, not just older adults — and the lean mass loss observed doesn't depend on already having established sarcopenia. In other words, a 25-, 30-, or 35-year-old who loses weight quickly on these medications, without strength training and without adequate protein, also loses muscle — and starts adult life with a smaller muscle reserve than they would otherwise have had. This matters because age-related sarcopenia begins silently around age 40: someone entering that phase with less muscle mass than they could have had starts from a less favorable position, not a neutral one.

That's why strength training and adequate protein intake aren't "optional" while using these medications, at any age — they're part of the care, with specific evidence that they significantly reduce this lean mass loss.5

Why this isn't just "an older person's issue"

Sarcopenia begins long before old age — the process is already underway from age 40 onward, silently. That means the right time to act isn't when the loss of strength is already noticeable day to day, but years earlier, already after 40.

What helps fight this process

The two strategies with the strongest scientific evidence aren't new, but they remain the most effective:

• Strength training is the most studied and most effective intervention for preserving (or rebuilding) muscle mass, strength, and physical performance throughout aging.5
• Adequate, individualized protein intake works together with exercise to sustain muscle mass — especially important during weight loss, when the risk of losing muscle along with fat increases.6

What to do with this information

This isn't an invitation to self-diagnose. Properly assessing your muscle mass, strength, and sarcopenia risk depends on clinical evaluation and, when indicated, complementary tests (such as grip strength dynamometry or body composition assessment) — not assumptions. If you're over 40 and have never stopped to think about this, this is a good reason to start.

References

1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al., for the Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. academic.oup.com
2. Xu J, Wan CS, Ktoris K, Reijnierse EM, Maier AB. Sarcopenia Is Associated with Mortality in Adults: A Systematic Review and Meta-Analysis. Gerontology. 2022;68(4):361-376. pubmed.ncbi.nlm.nih.gov
3. Srikanthan P, Karlamangla AS. Muscle Mass Index As a Predictor of Longevity in Older Adults. Am J Med. 2014;127(6):547-553. amjmed.com
4. Leong DP, Teo KK, Rangarajan S, et al., for the PURE Study Investigators. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273. thelancet.com
5. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. abcd.care
6. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. dom-pubs.onlinelibrary.wiley.com
7. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2024. sciencedirect.com
8. Nutritional and exercise interventions in individuals with sarcopenic obesity around retirement age: a systematic review and meta-analysis. 2023. pubmed.ncbi.nlm.nih.gov
9. Exercise and Protein Supplementation Recommendations for Older Adults With Sarcopenic Obesity: A Meta-Review. 2023. pubmed.ncbi.nlm.nih.gov

This content is educational and does not replace individual medical evaluation.